News

Genzyme has posted a net income of $68.95m for the third quarter 2010, or $0.26 per diluted share, compared to $16m, or $0.06 per diluted share, for the

Teplizumab, also called MGA031 and hOKT31 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. It is an investigational biologic under development for the treatment of individuals with recent-onset type

Appling and Johnston will be based in the company’s Queensbury, New York facility and report to the executive vice president of Research and Development, and Delcath’s chief medical

Breakyl (also known as Onsolis or BEMA Fentanyl) is indicated for the management of pain in opioid tolerant adult patients with cancer. Meda claims that Breakyl uses a

Abbott has posted net earnings of $891m for the third quarter 2010, or $0.57 per diluted share, compared to net earnings of $1.48bn, or $0.95 per diluted share,

Alcon has posted a net earnings of $446m for the third quarter 2010, or $1.47 per diluted share, compared to net earnings of $515m, or $1.71 per diluted

Previously, Parsons was the chief financial officer for both private and public life science companies including Amorfix Life Sciences, Trillium Therapeutics and Lorus Therapeutics. DiaMedica president and CEO

Under the partnership, HCPlexus and Healthline Networks are expected to extend their current advertising networks, as well as the new point-of-care information platform, to provide contextual and direct

The group will draw on expertise developed by the company in its ten years of building custom biomedical data management applications, Prometheus Research said. HTSQL is a software